Details of the Drug Reposition

General Information of This Drug (ID: DM8GFEV)

Drug Name
Atacicept   DM8GFEV

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Lymphoma DISN6V4S 2A80-2A86 Phase 3 [1]
------------------------------------------------------------------------------------
3 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Systemic lupus erythematosus DISI1SZ7 4A40.0 Phase 2 [2]
Multiple sclerosis DISB2WZI 8A40 Phase 2 [3]
Rheumatoid arthritis DISTSB4J FA20 Phase 2 [3]
------------------------------------------------------------------------------------

References

1 Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis. Nervenarzt. 2009 Dec;80(12):1462-72.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.